Natural Product (NP) Details
General Information of the NP (ID: NP7706) | |||||
---|---|---|---|---|---|
Name |
Tazarotene
|
||||
Synonyms |
tazarotene; 118292-40-3; Tazorac; Zorac; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Avage; AGN-190168; Fabior; AGN 190168; Tazarotene (Avage); UNII-81BDR9Y8PS; C21H21NO2S; 81BDR9Y8PS; CHEMBL1657; ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; CHEBI:32184; NCGC00167525-01; ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; DSSTox_CID_26691; DSSTox_RID_81825; DSSTox_GSID_46691; tazaroteno; tazarotenum; Suretin; Tazoral; Zora; 6-(4,4-Dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester; ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate;6-(4,4-dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester; Tazorac (TN); Avage (TN); CAS-118292-40-3; Acnitaz; ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)-ethynyl)nicotinate; Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate; Tazarotene (JAN/USAN/INN); Tazarotene [USAN:INN:BAN]; Zorac; ; ; Tazorac; Tazarotene,(S); ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate; Fabior (TN); 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; PubChem24431; SCHEMBL3134; MLS003915630; BIDD:GT0293; GTPL6952; DTXSID5046691; HMS3655K05; HMS3747C19; HMS3747E19; ACT06773; AMY31169; BCP22966; EBD38650; ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate; ZINC1542199; Tox21 112522; Tox21_112522; ABP000994; AC-755; ANW-45265; BDBM50265951; MFCD00867628; s1569; AKOS015902872; Tox21_112522_1; BS-1012; CCG-268046; CS-1029; DB00799; NCGC00167525-02; NCGC00167525-03; 6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester; HY-15388; SMR002096194; BCP0726000163; AB0012671; DB-014992; FT-0652578; SW220026-1; AGN190168, AGN-190168; C12531; D01132; S-7551; 15146-EP2275420A1; 15146-EP2295055A2; 15146-EP2295416A2; 15146-EP2298748A2; 15146-EP2298764A1; 15146-EP2298765A1; 15146-EP2298768A1; 15146-EP2305642A2; 15146-EP2308861A1; 15146-EP2311453A1; 15146-EP2311808A1; 15146-EP2311829A1; 15146-EP2314590A1; 15146-EP2316832A1; 15146-EP2316833A1; AB01274801-01; AB01274801_02; 292T403; SR-01000931253; Q-102516; Q3981685; SR-01000931253-2; Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate; 6-(4,4-dimethylthiochroman-6-ylethynyl) nicotinic acid ethyl ester; (+/-)OCTAHYDROCYCLOPENTA[B]PYRROLE-2-CARBOXYLICACIDHYDROCHLORIDE; 6-(2-(4,4-dimethyl-thiochroman-6yl)ethynyl)-nicotinic acid ethyl ester; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-pyridinecarboxylic Acid Ethyl Ester; 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester; 6-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylicacidethylester
Click to Show/Hide
|
||||
Species Origin | Homo sapiens ... | Click to Show/Hide | |||
Homo sapiens | |||||
Disease | Plaque psoriasis [ICD-11: EA90] | Approved | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C21H21NO2S
|
||||
PubChem CID | |||||
Canonical SMILES |
CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C
|
||||
InChI |
1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3
|
||||
InChIKey |
OGQICQVSFDPSEI-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 118292-40-3
|
||||
ChEBI ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Imiquimod | Skin cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Experimental
Result(s) |
Tazarotene enhanced the penetration of imiquimod, and could be a therapeutic option in cases where surgical intervention is not possible. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Retinoic acid receptor gamma (RARG) | Molecule Info | [3] | |
Reactome | Nuclear Receptor transcription pathway | Click to Show/Hide | ||
WikiPathways | Vitamin A and Carotenoid Metabolism | Click to Show/Hide | ||
2 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
3 | Mesodermal Commitment Pathway | |||
4 | Endoderm Differentiation | |||
5 | Nuclear Receptors |
